Epidemiology of biopsy-proven giant cell arteritis in South Australia

Internal Medicine Journal

Volumn 44, Issue 1, 2014, Pages 32-39

  Dunstan, E ^a,b   Lester, S L ^a   Rischmueller, M ^a,b   Dodd, T ^c   Black, R ^b   Ahern, M ^d   Cleland, L G ^e   Roberts Thomson, P ^f   Hill, C L ^a,b  

^a QUEEN ELIZABETH HOSPITAL   (Australia)

^b UNIVERSITY OF ADELAIDE   (Australia)

^c SA Pathology   (Australia)

^d REPATRIATION GENERAL HOSPITAL   (Australia)

^e ROYAL ADELAIDE HOSPITAL   (Australia)

^f FLINDERS UNIVERSITY   (Australia)

Author keywords

Epidemiology; Giant cell arteritis; Incidence; Vasculitis

Indexed keywords

CORTICOSTEROID; PREDNISOLONE; STEROID;

AGED; APPETITE DISORDER; ARTICLE; AUSTRALIA; BIOPSY; BLOOD VESSEL BIOPSY; CATARACT; CLAUDICATION; CLINICAL FEATURE; CORTICOSTEROID THERAPY; DEPRESSION; DIABETES MELLITUS; EDEMA; EPIDEMIOLOGICAL DATA; FEMALE; FRAGILITY FRACTURE; GASTROINTESTINAL SYMPTOM; GIANT CELL ARTERITIS; HEADACHE; HUMAN; HYPERGLYCEMIA; HYPERTENSION; JAW DISEASE; MAJOR CLINICAL STUDY; MALE; MOOD DISORDER; MOON FACE; OSTEOPOROSIS; PRIORITY JOURNAL; QUESTIONNAIRE; RHEUMATIC POLYMYALGIA; SEASONAL VARIATION; SKIN BRUISING; SLEEP DISORDER; TEMPORAL ARTERY; THRUSH; UNSPECIFIED SIDE EFFECT; VAGINA DISEASE; VERY ELDERLY; VISUAL DISORDER; WEAKNESS; WEIGHT GAIN;

EPIDEMIOLOGY; GIANT CELL ARTERITIS; INCIDENCE; VASCULITIS;

ADRENAL CORTEX HORMONES; AGED; AGED, 80 AND OVER; BIOPSY; COMORBIDITY; FEMALE; GIANT CELL ARTERITIS; HUMANS; INCIDENCE; MALE; REGISTRIES; RISK FACTORS; SEASONS; SOUTH AUSTRALIA; SYMPTOM ASSESSMENT; TEMPORAL ARTERIES;

EID: 84892846196     PISSN: 14440903     EISSN: 14455994     Source Type: Journal    
DOI: 10.1111/imj.12293     Document Type: Article

References (33)

1. Borchers AT, Gershwin ME. Giant cell arteritis: a review of classification, pathophysiology, geoepidemiology and treatment. Autoimmun Rev 2012; 11: A544-554.
2. Salvarani C, Cantini F, Hunder GG. Polymyalgia rheumatica and giant-cell arteritis. Lancet 2008; 372: 234-245.
3. Nesher G, Berkun Y, Mates M, Baras M, Rubinow A, Sonnenblick M. Low-dose aspirin and prevention of cranial ischemic complications in giant cell arteritis. Arthritis Rheum 2004; 50: 1332-1337.
4. Ghosh P, Borg FA, Dasgupta B. Current understanding and management of giant cell arteritis and polymyalgia rheumatica. Expert Rev Clin Immunol 2010; 6: 913-928.
5. Abdul-Rahman AM, Molteno AC, Bevin TH. The epidemiology of giant cell arteritis in Otago, New Zealand: a 9-year analysis. N Z Med J 2011; 124: 44-52.
6. Boesen P, Sorensen SF. Giant cell arteritis, temporal arteritis, and polymyalgia rheumatica in a Danish county. A prospective investigation, 1982-1985. Arthritis Rheum 1987; 30: 294-299.
7. Baldursson O, Steinsson K, Bjornsson J, Lie JT. Giant cell arteritis in Iceland. An epidemiologic and histopathologic analysis. Arthritis Rheum 1994; 37: 1007-1012.
8. Smeeth L, Cook C, Hall AJ. Incidence of diagnosed polymyalgia rheumatica and temporal arteritis in the United Kingdom, 1990-2001. Ann Rheum Dis 2006; 65: 1093-1098.
9. Salvarani C, Crowson CS, O'Fallon WM, Hunder GG, Gabriel SE. Reappraisal of the epidemiology of giant cell arteritis in Olmsted County, Minnesota, over a fifty-year period. Arthritis Rheum 2004; 51: 264-268.
10. Salvarani C, Macchioni P, Zizzi F, Mantovani W, Rossi F, Castri C etal. Epidemiologic and immunogenetic aspects of polymyalgia rheumatica and giant cell arteritis in northern Italy. Arthritis Rheum 1991; 34: 351-356.
11. Gonzalez-Gay MA, Miranda-Filloy JA, Lopez-Diaz MJ, Perez-Alvarez R, Gonzalez-Juanatey C, Sanchez-Andrade A etal. Giant cell arteritis in northwestern Spain: a 25-year epidemiologic study. Medicine (Baltimore) 2007; 86: 61-68.
12. Lee JL, Naguwa SM, Cheema GS, Gershwin ME. The geo-epidemiology of temporal (giant cell) arteritis. Clin Rev Allergy Immunol 2008; 35: 88-95.
13. R Core Team. R: A Language and Environment for Statistical Computing. Vienna: R Foundation for Statistical Computing; 2012.
14. Fox J. The R Commander: a basic statistics graphical user interface to R. J Stat Softw 2005; 14: 1-42.
15. 3101.0 Australian Demographic Statistics, Table 54: Estimated Resident Population by Single Year of Age, South Australia. December, 2011.
16. Barnett AG. Dobson AJ. Analysing Seasonal Health Data. Berlin, Heidelberg: Springer; 2010.
17. Barnett AG, Baker PJ, Dobson AJ. Season: Analysing Seasonal Data R Functions. The R Journal 2012; 4: 5-10.
18. Reinhold-Keller E, Zeidler A, Gutfleisch J, Peter HH, Raspe HH, Gross WL. Giant cell arteritis is more prevalent in urban than in rural populations: results of an epidemiological study of primary systemic vasculitides in Germany. Rheumatology (Oxford) 2000; 39: 1396-1402.
19. Haugeberg G, Paulsen PQ, Bie RB. Temporal arteritis in Vest Agder County in southern Norway: incidence and clinical findings. J Rheumatol 2000; 27: 2624-2627.
20. Petursdottir V, Johansson H, Nordborg E, Nordborg C. The epidemiology of biopsy-positive giant cell arteritis: special reference to cyclic fluctuations. Rheumatology (Oxford) 1999; 38: 1208-1212.
21. Hunder GG, Bloch DA, Michel BA, Stevens MB, Arend WP, Calabrese LH etal. The American College of Rheumatology 1990 criteria for the classification of giant cell arteritis. Arthritis Rheum 1990; 33: 1122-1128.
22. Bas-Lando M, Breuer GS, Berkun Y, Mates M, Sonnenblick M, Nesher G. The incidence of giant cell arteritis in Jerusalem over a 25-year period: annual and seasonal fluctuations. Clin Exp Rheumatol 2007; 25: S15-17.
23. Jonasson F, Cullen JF, Elton RA. Temporal arteritis. A 14-year epidemiological, clinical and prognostic study. Scott Med J 1979; 24: 111-117.
24. Elling P, Olsson AT, Elling H. Synchronous variations of the incidence of temporal arteritis and polymyalgia rheumatica in different regions of Denmark; association with epidemics of Mycoplasma pneumoniae infection. J Rheumatol 1996; 23: 112-119.
25. Lopez-Diaz MJ, Llorca J, Gonzalez-Juanatey C, Pena-Sagredo JL, Martin J, Gonzalez-Gay MA. Implication of the age in the clinical spectrum of giant cell arteritis. Clin Exp Rheumatol 2008; 26: S16-22.
26. Kobayashi S, Yano T, Matsumoto Y, Mumano F, Nakajima N, Yasuda K etal. Clinical and epidemiologic analysis of giant cell (temporal) arteritis from a nationwide survey in 1998 in Japan: the first government-supported nationwide survey. Arthritis Rheum 2003; 49: 594-598.
27. Dasgupta B, Borg FA, Hassan N, Alexander L, Barraclough K, Bourke B etal. BSR and BHPR guidelines for the management of giant cell arteritis. Rheumatology 2010; 49: 1594-1597.
28. Spies CM, Strehl C, van der Goes MC, Bijlsma JW, Buttgereit F. Glucocorticoids. Best Pract Res Clin Rheumatol 2011; 25: 891-900.
29. Mahr AD, Jover JA, Spiera RF, Hernandez-Garcia C, Fernandez-Gutierrez B, Lavalley MP etal. Adjunctive methotrexate for treatment of giant cell arteritis: an individual patient data meta-analysis. Arthritis Rheum 2007; 56: 2789-2797.
30. Hoffman GS, Cid MC, Rendt-Zagar KE, Merkel PA, Weyand CM, Stone JH etal. Infliximab for maintenance of glucocorticosteroid-induced remission of giant cell arteritis: a randomized trial. Ann Intern Med 2007; 146: 621-630.
31. Nuenninghoff DM, Matteson EL. The role of disease-modifying antirheumatic drugs in the treatment of giant cell arteritis. Clin Exp Rheumatol 2003; 21: S29-34.
32. Unizony SH, Dasgupta B, Fisheleva E, Rowell L, Schett G, Spiera R etal. Design of the tocilizumab in giant cell arteritis trial. Int J Rheumatol 2013; 2013: 912562.
33. Ninan J, Nguyen AM, Cole A, Rischmueller M, Dodd T, Roberts-Thomson P etal. Mortality in patients with biopsy-proven giant cell arteritis: a south Australian population-based study. J Rheumatol 2011; 38: 2215-2217.